Columnar-Cell Carcinoma: Another Variant of Poorly Differentiated Carcinoma of the Thyroid

1988 ◽  
Vol 89 (2) ◽  
pp. 264-267 ◽  
Author(s):  
Manuel Sobrinho-Simões ◽  
Jahn M. Nesland ◽  
Jan Vincents Johannessen
Keyword(s):  
Cell Carcinoma ◽  
Columnar Cell ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated

Single thyroid tumour showing multiple differentiated morphological patterns and intramorphological molecular genetic heterogeneity

2016 ◽  
Vol 70 (2) ◽  
pp. 116-119 ◽  
Author(s):  
Heather K Schopper ◽  
Aaron Stence ◽  
Deqin Ma ◽  
Nitin A Pagedar ◽  
Robert A Robinson
Keyword(s):  
Cell Carcinoma ◽  
Papillary Carcinoma ◽  
Clear Cell ◽  
The Other ◽  
Columnar Cell ◽  
Follicular Variant ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Cell Variant ◽  
Morphological Patterns

AimsA 49-year-old man presented with a single thyroid tumour that showed a combination of conventional papillary carcinoma, follicular variant of papillary carcinoma, clear cell papillary carcinoma, columnar cell carcinoma and poorly differentiated carcinoma. As all of the morphologies have been associated with papillary carcinoma in the literature, we wished to determine if they contained identical or different molecular abnormalities.MethodsTargeted next generation sequencing (NGS) of each morphological component and metastases was performed.ResultsNGS revealed a BRAF p.K601E mutation in both the clear cell papillary carcinoma and poorly differentiated carcinoma and a KRAS p.G12R mutation in the papillary carcinoma, follicular variant. Two different areas of columnar cell variant were tested, with one showing a KRAS p.G12D mutation but no mutation in the other area. A KRAS p.G12R mutation was seen in the metastatic clear cell variant. Two different lymph nodes had metastatic columnar cell carcinoma, one negative for mutations but the other with a compound KRAS p.G12R and KRAS p.G12V mutation on different alleles. No mutations including BRAF and KRAS were seen in the conventional papillary carcinoma.ConclusionsAlthough all of the morphological patterns in this tumour have been reported as having aetiological or other association with one another, there was only partial concordance with their molecular signatures. There was significant molecular discordance, however, even with identical morphologies.

Locally advanced scrotal squamous cell carcinoma: Does chemotherapy affect survival?

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 3-3
Author(s):  
Bhaskara Reddy Madhira ◽  
Gary Brooks ◽  
Rashad Khan ◽  
Komal Akhtar ◽  
Alina Basnet
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Group Versus ◽  
Small Sample ◽  
Cancer Center ◽  
P Value ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated

3 Background: Scrotal squamous cell carcinoma (SSCC)thoughrare, represents the most common forms of scrotal malignancies.40-50% of patients present with locally advanced disease, and treatment is extrapolated from penile cancer. Here we report practice trend and overall survival (OS) outcome of locally advanced SSCC patients who underwent surgery with or without chemotherapy. Methods: We performed a retrospective analysis using the national cancer center database (NCDB) (2004-2016). All patients aged ≥ 18 years with locally advanced SSCC who underwent surgery with or without chemotherapy were included. OS is estimated with Kaplan-Meier curves, with an adjusted hazard ratio (aHR) calculated from Cox proportional hazard regression model. Results: 638 patients were identified with SSCC without distant metastasis. Of these 49 underwent surgery with perioperative chemotherapy and 589 underwent surgery alone. At the median follow up of 39.9 months (mo), median OS is 41.4 mo and 145.7 mo for surgery with chemotherapy group versus surgery alone respectively (P-value <0.0001), with aHR for OS 1.673 (95%CI 0.966-2.897). Patients age ≥ 65 (HR= 3.081, 95% CI=2.107- 4.505, p<0.001), Charlson-Deyo Score (CCI) 2 or more (HR=3.441, 95% CI=2.140- .533, p <0.0001), moderately-poorly differentiated carcinoma (HR=1.713, 95% CI=1.038- 2.829, p=0.0352), and higher clinical nodal status N1,N2 and N3 (HR=2.543, 95% CI=1.42-4.548, p=0.0016)were observed to do worse with surgery and chemotherapy. Patients with CCI of 2 or more, moderate to poorly differentiated carcinoma, higher clinical T and N stage (T2- T4 and N1-N3 respectively) were observed more likely to receive surgery and chemotherapy. Conclusions: No OS improvement was seen in locally advanced SSCC with addition of chemotherapy to surgery. Patients who received chemotherapy along with surgery are observed to have higher risk of mortality vs surgery alone. The study is limited by retrospective nature, lack of randomization, patient selection bias, patient’s choice of therapy, small sample size, and missing information.

scholarly journals Role of immunohistochemistry in cell block sections for categorization of non-small cell carcinoma of lung

2019 ◽  
Vol 9 (3) ◽  
pp. 223-228
Author(s):  
Shamoli Yasmin ◽  
Wasim Selimul Haque ◽  
Sk Md Jaynul Islam ◽  
Mostare Khondoker ◽  
Susane Giti
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Cell Block ◽  
Lung Mass ◽  
Benign Lesions ◽  
Ct Guided ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Mass Lesions

Background: Computed tomography (CT) guided fine needle aspiration and cytology (FNAC) is a useful modality which aids in early and fairly accurate diagnosis of mass lesions of lungs specially the malignant ones. Previously in patients with primary lung cancer the most important consideration was to discriminate between small cell and non-small cell carcinoma (NSCC) of the lung. With advancement of cancer therapy, sub-typing of NSCC has become very important. The aims of the study were to evaluate the pathological spectrum of the pulmonary diseases in CT guided FNAC of lung mass lesions and utility of limited immunohistochemistry (IHC) in cell block sections to subcategorize NSCC. Methods: The study was carried out at Department of Histopathology in Armed Forces Institute of Pathology from 1st January 2018 to 31st December 2018. It involved total 140 patients who underwent CT guided FNAC in Combined Military Hospital, Dhaka for lung mass lesions. Aspiration was done by pathologist and obtained material was used to make slide smears and cell blocks. Both FNAC smears and cell block sections were examined by histopathologists. The entities diagnosed as NSCC and poorly differentiated carcinomas in FNAC were treated with limited IHC panel in cell block sections. Results: Out of 140 cases 110 were male and 30 were female patients. Age range was from 18 to 85 years, (mean age 60±13.5). Total 83(59%) malignant neoplasms and 57(41%) benign lesions were diagnosed. Among the benign lesions, 28 were diagnosed as granulomatous lesion suggestive of tuberculosis and rests were nonspecific inflammatory lesion. In FNAC smear, small cell carcinoma was diagnosed in 16.9% (14/83) of all malignant lesions, squamous cell carcinoma (SCC) in 26.5% (22/83) patients and adenocarcinoma in 22.9% (19/83) patients. Twenty-five patients were categorized as NSCC as they could not be further subcategorized in FNAC as SCC/adenocarcinoma. Three patients were categorized as poorly differentiated carcinoma as their cytological features could not rule in/out small cell carcinoma. NSCC and poorly differentiated carcinoma diagnosed by FNAC were33.7% (28/83). Cell blocks of all of them were examined, three of NSCC cell blocks were found inadequate for evaluation. All of the rest cases underwent limited IHC panel in cell block sections and were further subcategorized; 13 as SCC and 12 as adenocarcinoma. Total cases of SCC diagnosed in the study after IHC on cell block sections were 35/83(42%) followed by adenocarcinoma 31/83, (33.35%). Conclusion: CT guided FNAC is an effective tool and can be used for fairly accurate and early diagnosis of lung mass lesions. Immunohistochemistry on cell block sections can be used as an effective tool for categorization of NSCC. Birdem Med J 2019; 9(3): 223-228

scholarly journals Co-existence of lung carcinoma metastasis and enchondroma in the femur of a patient with Ollier disease

2020 ◽  
Author(s):  
Xudong Wang ◽  
Xiaohui Zhang ◽  
Wenling Pan ◽  
Yuedong Han ◽  
Yanwei Li ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Distal Femur ◽  
Proximal Tibia ◽  
Left Femur ◽  
Tumour Metastasis ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Ollier Disease

Abstract Tumour-to-tumour metastasis is very unusual and has been defined as a tumour metastasis into another histologically different tumour. It is extremely rare in bone. We report a case of lung squamous cell carcinoma metastasized to an enchondroma in the femur of a patient with Ollier disease. A 60-year-old female had a history of a poorly differentiated squamous cell carcinoma of the lung. She underwent a video-assisted thoracoscopic lobectomy, and a follow-up MRI scan showed three lesions in the left distal femur and proximal tibia, which were initially interpreted as metastasis on radiology. Resection of the left proximal tibial lesion was performed, and the pathological findings were consistent with enchondroma with no evidence of metastasis. Subsequent curettage of lesions in the distal left femur revealed metastatic poorly differentiated carcinoma with foci of hyaline cartilage, which was most consistent with metastatic carcinoma in a pre-existing enchondroma. The MRI films were re-reviewed. Characteristic MRI features of enchondroma were found in the lesion in the left proximal tibia and one of the lesions in the left distal femur, while the features of the other lesion in the left distal femur included cortical destruction and extensive oedema in surrounding soft tissue, which were consistent with a malignant tumour. In addition, the enchondroma in the lateral condyle showed blurring and irregular inner margin and adjacent bone oedema, which likely represents a co-existing metastatic tumour and enchondroma. The difference in lineage was confirmed by immunohistochemistry. The final diagnosis was metastatic poorly differentiated carcinoma of the lung into a co-existent enchondroma. The diagnosis can be challenging and could be easily overlooked both radiologically and histologically. Thorough clinical and radiological information is critical for the diagnosis, and despite a very unusual event, awareness of the tumour-to-tumour metastasis phenomenon can avoid an inaccurate diagnosis by the pathologist, therefore preventing inappropriate clinical intervention.

scholarly journals Metastatic Basal Cell Carcinoma

2019 ◽  
Vol 152 (6) ◽  
pp. 706-717 ◽  
Author(s):  
Alvaro C Laga ◽  
Inga Marie Schaefer ◽  
Lynette M Sholl ◽  
Christopher A French ◽  
John Hanna
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Molecular Genetic ◽  
Molecular Testing ◽  
Squamous Differentiation ◽  
Primary Tumors ◽  
Poorly Differentiated Carcinoma ◽  
Metastatic Basal Cell Carcinoma ◽  
Poorly Differentiated

Abstract Objectives Diagnosis of metastatic basal cell carcinoma (BCC) remains challenging, in part due to its rarity. With the advent of molecularly targeted therapies, recognition of this entity is more important than ever. Methods We identified 11 cases of metastatic BCC over a 13-year period. We analyzed these tumors in conjunction with their respective primary tumors by histomorphologic, immunohistochemical, and molecular genetic analyses. Results We identified three morphologic patterns of metastasis in BCC. The most common (seven cases) was characterized by completely typical features of BCC. Two cases showed marked squamous differentiation within BCC. The final two cases showed exclusively features of a poorly differentiated carcinoma. One of these was definitively classified by molecular analysis, as both the primary and metastatic tumors harbored the same inactivating PTCH1 mutation. Conclusions This study illustrates multiple distinct morphologic patterns in metastatic BCC and highlights the utility of ancillary molecular testing for accurate diagnosis.

scholarly journals Cutaneous squamous cell carcinoma arising in hidradenitis suppurativa: A case report

2019 ◽  
Vol 7 ◽  
pp. 2050313X1984735 ◽  
Author(s):  
Catherine F Roy ◽  
Simon F Roy ◽  
Feras M Ghazawi ◽  
Erica Patocskai ◽  
Annie Bélisle ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Hidradenitis Suppurativa ◽  
Rare Complication ◽  
Excisional Biopsy ◽  
Necrosis Factor Alpha ◽  
Spindle Cells ◽  
Poorly Differentiated ◽  
Well Differentiated

We present a case of a 64-year-old man who presented with a rapidly growing tumor in the left buttock and intergluteal cleft area, which was affected by hidradenitis suppurativa. The patient was on tumor necrosis factor-alpha inhibitors for hidradenitis suppurativa for 2 years prior to the development of the mass. Initial biopsy of the mass showed a well-differentiated squamous cell carcinoma with spindle cells and positive epithelial immunomarkers. Subsequent excisional biopsy of the tumor showed an infiltrating poorly differentiated squamous cell carcinoma composed of islands of atypical sarcomatoid spindle cells. Squamous cell carcinoma arising in hidradenitis suppurativa is a rare complication which may occur secondary to chronic inflammation and epidermal hyperproliferation in hidradenitis suppurativa–affected areas.

scholarly journals Challenging Diagnosis in NUT Carcinoma

2021 ◽  
pp. 106689692110195
Author(s):  
Grosse Claudia ◽  
Grosse Alexandra
Keyword(s):  
Nuclear Protein ◽  
Hematological Malignancy ◽  
Undifferentiated Carcinoma ◽  
Squamous Differentiation ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Nut Carcinoma ◽  
Disseminated Disease ◽  
Generation Sequencing

Nuclear protein in testis (NUT) carcinoma represents a highly aggressive, poorly differentiated carcinoma that is genetically defined by rearrangement of NUT gene. The histomorphological appearance ranges from entirely undifferentiated carcinoma to carcinoma with prominent squamous differentiation. NUT carcinoma can display neuroendocrine features. Although it is typically distributed along the midline axis, it may manifest in nonmidline locations. The majority of patients develop rapidly disseminated disease. We illustrate 2 cases of NUT carcinoma, one located in the lung, which closely resembled a neuroendocrine carcinoma, and the other one with assumed lung origin demonstrating metastatic dissemination with diffuse bone involvement, which was clinically first suspected to be a hematological malignancy. Due to its undifferentiated nature, NUT carcinoma may be confused with many entities. NUT immunohistochemistry is considered to be sufficient for the diagnosis. Fluorescence in-situ hybridization analysis and next-generation sequencing are currently used to confirm the diagnosis.

Poorly differentiated small cell carcinoma of the pancreas

Pancreatology ◽  
2004 ◽  
Vol 4 (6) ◽  
pp. 521-526 ◽  
Author(s):  
Simone Berkel ◽  
Frank Hummel ◽  
Jochen Gaa ◽  
Walter Back ◽  
Ralf Hofheinz ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Carcinoma Of The Pancreas ◽  
Poorly Differentiated
Sign in / Sign up

Export Citation Format

Share Document